Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis

Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases

(2017) Sinead O'Sullivan et al.   NEUROPHARMACOLOGY

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?

(2016) Frédéric J Zécri   CURRENT OPINION IN CHEMICAL BIOLOGY

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation

(2016) Hsing-Chuan Tsai et al.   DRUGS

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

(2016) Douglas R Jeffery et al.   Expert Review of Neurotherapeutics

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures

(2016) Catherine O’Sullivan et al.   Journal of Neuroinflammation

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?

(2016) Marine Boudot de la Motte et al.   Multiple Sclerosis Journal

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

(2016) Douglas R Jeffery et al.   Expert Review of Neurotherapeutics

Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis

(2016) Edward R. Hammond   JAMA Neurology

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis

(2016) Ludwig Kappos et al.   JAMA Neurology

Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?

(2016) Marine Boudot de la Motte et al.   Multiple Sclerosis Journal

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

(2015) Laura Ordoñez-Boschetti et al.   ADVANCES IN THERAPY

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

(2015) Adnan M. Subei et al.   CNS DRUGS

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

(2015) Samuel F. Hunter et al.   CNS DRUGS

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

(2015) Jeffrey A Cohen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice

(2015) T Ziemssen et al.   VALUE IN HEALTH

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Modulators of the Sphingosine 1-phosphate receptor 1

(2013) Mariangela Urbano et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study

(2013) Patrick Brossard et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator

(2013) Shifeng Pan et al.   ACS Medicinal Chemistry Letters

Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects

(2012) Eric Legangneux et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

(2012) P Gergely et al.   BRITISH JOURNAL OF PHARMACOLOGY

Early tolerability and safety of fingolimod in clinical practice

(2012) Daniel Ontaneda et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Sudden unexpected death on fingolimod

(2012) JW Lindsey et al.   Multiple Sclerosis Journal

Fingolimod-associated macular edema: Incidence, detection, and management

(2012) N. Jain et al.   NEUROLOGY

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Delayed fingolimod-associated asystole

(2011) Patricio S Espinosa et al.   Multiple Sclerosis Journal

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Fingolimod is a potential novel therapy for multiple sclerosis

(2010) Orhan Aktas et al.   Nature Reviews Neurology

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE